
RYBREVANT® (Amivantamab-Vmjw) Plus LAZCLUZETM (Lazertinib) Outperforms Osimertinib With A Significant And Unprecedented ...
(MENAFN- PR Newswire) Median overall survival not yet reached with projected improvement of more than one year versus osimertinib RARITAN, N.J., March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ ) today announced results for the gold …